5BARz International Inactive 10-Q11 Dec 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 18, 2013
Document And Entity Information	'	'
Entity Registrant Name	'5Barz International, Inc.	'
Entity Central Index Key	'0001454124	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	160,038,990
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash	$143,754	$48,308
Prepaid expenses and deposits	61,075	22,156
TOTAL CURRENT ASSETS	204,829	70,464
Equipment, net	7,015	4,406
OTHER ASSETS:	'	'
Intangible assets	3,387,406	3,387,406
Goodwill	1,140,246	1,140,246
Total other assets	4,527,652	4,527,652
TOTAL ASSETS	4,739,496	4,602,522
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses	2,562,262	2,445,410
Due to escrow agent	52,321	52,321
Accrued derivative liabilities	60,772	'
Notes payable (net of discount)	1,089,882	993,554
TOTAL CURRENT LIABILITIES	3,765,237	3,491,285
Related party loans	472	19,850
TOTAL LIABILITIES	3,765,709	3,511,135
STOCKHOLDERS' EQUITY	'	'
Common stock, $.001 par value, 250,000,000 shares authorized; 138,403,772 and 117,418,281 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	138,404	117,418
Capital in excess of par value	5,179,130	3,226,802
Deficit accumulated during the development stage	-4,989,290	-2,971,099
Accumulated other comprehensive income	27,250	4,272
Non-controlling interest	618,293	713,994
Total stockholders' equity	973,787	1,091,387
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$4,739,496	$4,602,522

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	138,403,772	117,418,281
Common stock,outstanding	138,403,772	117,418,281

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		59 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'	'
Sales	'	'	'	'	'
Cost of Sales	'	'	'	'	'
Selling general and administrative expenses:	'	'	'	'	'
Amortization and depreciation	495	831	1,623	2,689	6,196
Bank charges and interest	15,889	2,957	44,857	140,881	280,720
Sales and marketing expenses	36,514	7,871	127,882	94,635	472,295
Research & development	201,958	'	305,958	0	305,958
General and administrative expenses	770,506	332,403	1,753,912	1,507,354	4,388,309
Total operating expenses	1,025,362	344,062	2,234,231	1,745,559	5,453,477
(Loss) from operations	-1,025,362	-344,062	-2,234,231	-1,745,559	-5,453,477
Other income (expense):	'	'	'	'	'
Interest income	'	-1,128	'	1,212	16,666
Currency gains (losses)	'	'	'	'	-567
Change in fair value of derivative liability	-1,346	-147,530	-52,594	-75,556	577,492
Amortization of debt discount on derivative liability	'	-74,623	'	-92,288	-132,897
Loss on termination of finance agreements	'	'	'	'	-152,676
Other	86,060	'	172,933	-1,537	169,797
Total Other income (expense)	84,715	-225,195	120,339	-168,169	477,815
Net (loss) before non-controlling interest	-940,647	-569,258	-2,113,892	-1,915,642	-4,975,662
Non-controlling interest share of net loss	-4,577	139	-95,701	446,013	13,628
Net loss after non-controlling interest	-936,070	-569,397	-2,018,191	-2,361,655	-4,989,290
Basic (loss) per common share	($0.01)	($0.01)	($0.02)	($0.02)	'
Weighted average number of shares outstanding	125,414,735	108,607,401	118,545,298	102,081,180	'
Other comprehensive income	'	'	'	'	'
Foreign currency translation gain (loss)	11,227	-2,054	22,979	-1,735	'
Other comprehensive income	11,227	-2,054	22,979	-1,735	'
Comprehensive (loss)	($924,843)	($571,451)	($1,995,212)	($2,363,390)	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended		59 Months Ended
Condensed Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($2,113,892)	($1,915,642)	($4,975,662)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	1,623	2,689	5,612
Stock based compensation	515,123	'	522,236
Change in fair value of derivative liability	60,772	240,478	-480,678
Change in debt discount on convertible notes	'	1,336,129	152,821
Change in warrant liability	'	5,120	14,968
Common shares issued for services	220,139	452,990	1,064,852
Changes in operating assets and liabilities:	'	'	'
Change in accounts payable and accrued expenses	319,260	506,279	891,747
Change in prepaid expenses and deposits	-38,920	3,053	-41,700
Change in unpaid interest and penalties on notes payable	-44,545	91,507	342,096
Change in amount due to escrow agent	'	'	52,322
Net cash from (used in) operating activities	-1,080,440	-479,913	-2,451,387
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Deposit on investment in Cellynx	'	'	-170,000
Cash in Cellynx - date of acquisition	'	'	3,260
Acquisition of intangible assets	'	'	-4,808
Purchase of furniture and equipment assets	-3,103	'	-7,756
Net cash used in investing activities	-3,103	'	-179,304
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Payments under line of credit agreement Cellynx	'	-83,156	-250,152
Payment of amount due to Cellynx - intellectual property acquisition	'	'	-242,865
Proceeds from issuance of convertible notes	35,000	258,500	442,139
Payments of amounts due to related party	-19,378	-97,612	-463,701
Proceeds used to settle notes payable	-151,584	-95,942	-219,901
Proceeds from issuance of common stock	1,196,750	279,628	3,106,597
Proceeds from issuance of common stock by subsidiary - 5BARz AG	95,222	221,615	375,078
Net cash provided by financing activities	1,156,010	483,033	2,747,194
Effect of foreign currency exchange	22,979	-1,735	27,251
NET INCREASE IN CASH	95,446	1,385	143,754
CASH, BEGINNING OF PERIOD	48,308	49,209	'
CASH, END OF PERIOD	143,754	50,594	143,754
Supplementary disclosure of cash flow information	'	'	'
Cash paid for interest	13,374	15,534	70,194
NON-CASH INVESTING AND FINANCING ACTIVITIES	'	'	'
Common stock issued upon acquisition of Cellynx Group, Inc.	'	250,000	250,000
Settlement of prepaid deposit upon acquisition of Cellynx Group, Inc.	'	170,000	170,000
Fair market value of notes converted upon acquisition of Cellynx Group, Inc.	'	455,000	521,200
Fair market value of net assets acquired	'	875,000	875,000
Conversion of notes payable - Cellynx Group,Inc	7,200	81,000	76,200
Investment in Cellynx intellectual property for shares	'	1,800,000	1,800,000
Replacement of common shares acquired with a convertible note	80,000	'	80,000
Issuance of convertible note in lieu of accounts payable	147,428	'	147,428
Shares issued to settle interest on notes payable	7,500	'	7,500
Settlement of accounts payable with common stock	$31,250	'	$31,250

Organization_Going_Concern_and

Organization, Going Concern and Development Stage	9 Months Ended
Organization, Going Concern and Development Stage	Sep. 30, 2013
Notes to Financial Statements	'
Organization, Going Concern and Development Stage	'
	Note 1 – Organization, Going Concern and Development Stage

	The Company was incorporated under the laws of the State of Nevada on November 14, 2008. The Company was originally named “Bio-Stuff” and was a designated shell corporation from inception to the date of acquisition of the 5BARz assets.

	On December 29, 2010 the Company changed its name to 5BARz International, Inc. and on December 30, 2010, the Company acquired from CelLynx Group, Inc. the rights to certain intellectual property underlying the 5BARz products, a highly engineered wireless technology referred to as a “cellular network infrastructure device”. The 5BARz device captures cell signal and provides a smart amplification and resend of that cell signal giving the user improved cellular reception in their home, office or while mobile. On March 29, 2012, 5BARz International, Inc. acquired a 60% controlling interest in CelLynx Group, Inc.

	On November 6, 2011, the Company incorporated a subsidiary Company in Zurich, Switzerland called 5BARz AG which is a 94.4% held subsidiary at September 30, 2013. This entity has been granted the license for the marketing and distribution rights for 5BARz products in Germany, Austria and Switzerland.

	These financial statements reflect the financial position for the Company and its subsidiary companies 5BARz AG, CelLynx Group Inc. and its wholly owned subsidiary CelLynx Inc. as at September 30, 2013. Results of operations include those operations for subsidiaries acquired from the date of acquisition.

	Going concern

	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is a development stage company and has not commenced planned principal operations. As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses for the period from November 14, 2008 (date of inception) through September 30, 2013 of $4,975,662. The Company has negative cash flows from operations since inception of $2,451,387 and has an accumulated deficit of $4,989,290 at September 30, 2013. The Company has made no revenue to date. The Company is seeking additional sources of equity or debt financing, and there is no assurance these activities will be successful. These factors raise substantial doubt about the Company’s ability to continue as a going concern and the Company’s continued existence is dependent upon adequate additional financing being raised to develop its sales and marketing program for the sales of 5BARz product and commence its planned operations.

	The Company is in default on certain notes payable. Accordingly, any penalties and interest has been accrued as of September 30, 2013 (see Note 7).

	The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

	Development stage

	The Company is considered to be a development stage entity as defined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915. The Company has been a development stage entity since November 14, 2008 its inception. The Company has not generated any revenues to date.

Summary_of_significant_account

Summary of significant accounting policies

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 2 - Summary of significant accounting policies

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013, are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on May 13, 2013 for the fiscal year ended December 31, 2012.

The accompanying consolidated financial statements include the accounts of 5BARz International Inc., and its 94.4% owned subsidiary, 5BARz AG, and it’s 60% owned subsidiary CelLynx Group, Inc. and that Company’s 100% owned subsidiary CelLynx, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

Use of estimates

The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include impairment analysis for long lived assets, income taxes, litigation and valuation of derivative instruments. Actual results could differ from those estimates.

Intangible assets

Acquired patented and unpatented technology, licensing rights and trademarks are capitalized at their fair value. The legal costs, patent registration fees, and models and drawings required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated with applications that are not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident increase in the value of the patents are capitalized.

Capitalized costs for patents are amortized on a straight-line basis over the remaining twenty-year legal life of each patent after the costs have been incurred. Once each patent or trademark is issued, capitalized costs are amortized on a straight-line basis over a period not to exceed 20 years and 10 years, respectively. All research and development costs incurred in developing the patentable idea are expensed as incurred. The licensing right is amortized on a straight-line basis over a period of 10 years. Based on its review, the Company concluded that as of September 30, 2013 and December 31, 2012 there was no impairment of its intangible assets.

Goodwill

Generally accepted accounting principles in the United States require the Company to perform a goodwill impairment test annually and more frequently when negative conditions or a triggering event arise. After an assessment of certain qualitative factors, if it is determined to be more likely than not that the fair value of a reporting unit is less than its carrying amount, entities must perform the quantitative analysis of the goodwill impairment test. Based on its review, the Company concluded that as of September 30, 2013 there was no impairment of its goodwill.

Foreign currency translation

Transactions in foreign currencies have been translated into US dollars using the temporal method. The functional currency of the Company’s subsidiary 5BARz AG, is its local currency (Swiss Franc – CHF). Under this method, monetary assets and liabilities are translated at the year-end exchange rate. Non-monetary assets have been translated at the historical rate of exchange prevailing at the date of the transaction. Expenses have been translated at the exchange rate at the time of the transaction. Realized and unrealized foreign exchange gains and losses are included in operations.

Fair value of financial instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these instruments.

Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

•

Level 1. Quoted prices in active markets for identical assets or liabilities.

•

Level 2. Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

•

Level 3. Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the assets that are measured at fair value on a recurring basis.

Consolidated

Quoted Prices in Active Markets for Identical Assets or Liabilities

Quoted Prices for Similar Assets or Liabilities in Active Markets

Significant

Balance Sheet

(Level 1)

(Level 2)

Unobservable

Inputs

(Level 3)

Derivative Liabilities:

30-Sep-13

60,772

—

60,772

31-Dec-12

—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

30-Sep-13

Beginning balance

—

Change in fair value of derivative liabilities

60,772

Ending balance

60,772

The derivative conversion feature liabilities are measured at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:

30-Sep-13

Stock price

0.14

Volatility

240

Risk-free interest rate

0.04

Dividend yield

Expected life

0.002 years

Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivate liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, which reports to the Chief Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department with support from the Company’s consultants and which are approved by the Chief Financial Officer.

Level 3 financial liabilities consist of the derivative liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

The Company uses the Black-Scholes option valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as, volatility.

As of September 30, 2013 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.

Derivative instruments

The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging”. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.

Net loss per share

The Company reports loss per share in accordance with the ASC Topic 260, “Earnings Per Share.”, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities were not included in the calculation of loss per common share for the three and nine months ended September 30, 2013 or 2012 because their effect would be anti-dilutive. The weighted average number of shares outstanding does not include reciprocal shareholdings, held by the Company’s subsidiary, CelLynx Group, Inc. which is reflected as a reduction in capital in excess of par value on the Company’s balance sheet.

Stock Based Compensation

The Company reports stock-based compensation under ASC 718 “Compensation – Stock Compensation”. ASC 718 requires all share-based payments to employees, including grants of employee stock options, warrants to be recognized in the consolidated financial statements based on their fair values. The Company accounts for equity instruments issued to non-employees as compensation in accordance with the provisions of ASC 718, which require that each such equity instrument be recorded at its fair value on the measurement date, which is typically the date the services are performed. The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The model includes subjective input assumptions that can materially affect the fair value estimates. The model was developed for use in estimating the fair value of traded options or warrants. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or options granted

Reclassifications

Certain reclassifications have been made in the financial statements at September 30, 2012 and for the three and nine months then ended to conform to the September 30, 2013 presentation. The reclassifications had no effect on net loss.

Recent accounting pronouncements

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2013 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2013 or 2012, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

Acquisition_of_CelLynx_Group_I

Acquisition of CelLynx Group, Inc.	9 Months Ended
Acquisition of CelLynx Group, Inc.	Sep. 30, 2013
Notes to Financial Statements	'
Acquisition of CelLynx Group, Inc.	'
	Note 3 – Acquisition of CelLynx Group, Inc.

	On January 7, 2011 the Company entered into a stock purchase agreement with two founding shareholders of CelLynx Group, Inc. to acquire in aggregate 63,412,638 shares of the capital stock of CelLynx Group, Inc. for total proceeds of $634,126. At that date the Company had paid $170,000 as a deposit made under that agreement. On March 29, 2012 the Company entered into a securities exchange agreement and settlement agreement with each of the two founding shareholders of CelLynx Group, Inc. whereby in addition to the $170,000 paid, the Company issued 1,250,000 shares of its common stock in exchange for the 63,412,638 shares of CelLynx Group, Inc. and mutual releases were signed between the parties releasing each from any further obligation.

	On March 29, 2012, the Company acquired a further interest in CelLynx Group, Inc. by conversion of $73,500 of convertible debt in CelLynx Group, Inc for the issuance of 350,000,000 shares in the capital stock of CelLynx Group, Inc. As a result, in combination with the shares acquired from existing shareholders referred to above, the registrant acquired a 60% controlling interest in CelLynx Group, Inc. and has accounted for that acquisition as a consolidated subsidiary of the registrant effective March 29, 2012.

	The purchase price, which was settled in cash, shares, and the settlement of convertible debt was $875,000, as follows:

	i.		Cash consideration paid		$	170,000
	ii.		1,250,000 common shares of the registrant issued at a market price of $0.20 per share			250,000
	iii.		Redemption of convertible debt for 350 million shares of CelLynx Group Inc. common stock			455,000	(a)
	Fair market value of consideration paid				$	875,000

		(a)	The valuation of the debt instrument with an embedded conversion feature is calculated at the face value of the debt instrument of $73,500 plus the intrinsic value attributable to the conversion of the debt instrument at a 75% discount to market, based upon the lowest 3 closing bid prices of the common stock for a period of 30 days prior to the date of conversions. That intrinsic valuation is calculated to be $ 381,500. The amounts recognized for each class of the acquiree’s assets and liabilities recognized at the acquisition date, March 29, 2012 are as follows:

	The amounts recognized for each class of the acquiree’s assets and liabilities recognized at the acquisition date, March 29, 2012 are as follows;

	Description		Net book value of CelLynx Group, Inc. consolidated assets and liabilities				Acquisition			Valuation attributed to assets acquired
	Description						Adjustments (i) (ii)			Valuation attributed to assets acquired
	Current assets		$	3,260						$	3,260
	Patented and unpatented technology, trademarks, and license			44,718			$	1,155,282	(ii)		1,200,000
	Investment in 5BARz (iii)			1,800,000							1,800,000
	Furniture and equipment			2,113							2,113
	Accounts payable and accruals			(1,752,628	)						(1,752,628	)
	Notes payable (net of discount)			(403,076	)						(403,076	)
	Accrued interest			(62,250	)						(62,250	)
	Derivative liability			(5,495,425	)			5,026,093	(i)		(469,332	)
	LOC payable – 5BARz (net)			(586,525	)			586,525	(i)		—
	Fair value non-controlling interest							(583,333	)		(583,333	)
	Totals		$	(6,449,813	)		$	6,184,567			(265,246	)
	Goodwill										1,140,246
	Purchase price									$	875,000

		(i)	In determining the fair value of assets acquired, the Company eliminated the convertible debt owed to 5BARz and the derivative liability attributed to that debt.
		(ii)	Fair value of technology, trademarks and license.
		(iii)	Eliminates in consolidation

	On April 13, 2012 the Company exercised $7,700 under the terms of the convertible line of credit agreement with CelLynx Group, Inc. to acquire a further 51,333,333 shares in the capital stock of CelLynx Group, Inc. On May 15, 2012 the Company exercised a further $58,500 to acquire a further 390,000,000 shares and on May 21, 2013 the Company acquired 375,000,000 shares on the conversion of $9,375 under the convertible line of credit agreement. Each conversion increased the percentage ownership that the Company holds in CelLynx Group, Inc. to a 60% interest, subsequent to dilution arising from 3^rd party convertible note conversions. At September 30, 2013 the Company had a 60% equity ownership in CelLynx Group, Inc.

Investment_in_5BARz_AG

Investment in 5BARz AG	9 Months Ended
Investment in 5BARz AG	Sep. 30, 2013
Notes to Financial Statements	'
Investment in 5BARz AG	'
	Note 4 – Investment in 5BARz AG

	On October 6, 2011, the Company incorporated a subsidiary Company under the laws of Switzerland, in the Canton of Zurich, called 5BARz AG. 5BARz AG issued 10,000,000 common shares of which 5,100,000 are held by the Company, 450,000 are held by officers and a consultant to the Company and 4,450,000 were held in escrow for resale, by an independent escrow agent under the control of the Company. 5BARz AG issued the shares with a stated or par value of CHF 0.01 per share for proceeds of CHF 100,000 (US - $108,752). The net proceeds received on re-sale above the stated or par value of the shares, is paid into 5BARz AG as additional paid in capital. During the period from inception (October 6, 2011) to September 30, 2013, sales of those securities aggregated 122,000 shares sold for proceeds of $366,000 CHF ($372,728 USD). At September 30, 2012 the Company holds a 94.3% controlling interest in 5BARz AG represented by 9,428,000 shares. During the 9 month period ended September 30, 2013 the Company sold 30,000 of the securities that it holds in 5BARz AG and the controlling interest in 5BARz AG was reduced by 0.3% to a 94.3% controlling interest.

	On October 19, 2011, the registrant, 5BARz International Inc. entered into a Marketing and Distribution agreement with 5BARz AG, through which 5BARz AG holds the exclusive rights for the marketing and distribution of products produced under the 5BARz brand for markets in Switzerland, Austria and Germany. That agreement does not have a royalty payment requirement, and remains effective as long as 5BARz AG is controlled by the Company. 5BARz AG is a consolidated subsidiary of the Company in these financial statements.

Intangible_assets_and_goodwill

Intangible assets and goodwill	9 Months Ended
Intangible assets and goodwill	Sep. 30, 2013
Notes to Financial Statements	'
Intangible assets and goodwill	'
	Note 5 – Intangible assets and goodwill

	Intangible assets are comprised of patented and unpatented technology, trademarks and license rights which are recorded at cost, comprised of legal fees and acquisition costs. Once each patent or trademark is issued, capitalized costs are amortized on a straight-line basis over a period not to exceed 20 years and 10 years, respectively. License rights are amortized over the period of the respective license agreement.

			30-Sep-13		31-Dec-12
	Patented and unpatented technology	$	3,015,794	$	3,015,794
	Marketing and distribution agreement		370,000		370,000
	Trademarks		264		264
	License rights		1,348		1,348
		$	3,387,406	$	3,387,406
	Accumulated amortization				—
	Patents and other intangibles, net	$	3,387,406	$	3,387,406


	During the nine months ended September 30, 2013 and year ended December 31, 2012 no amortization has been recorded on technology and other intangibles. The intangible assets acquired on December 29, 2011 related to the 5BARz technology will commence amortization with the initial commercial production (commercial viability) of products incorporating the related technology. The Company’s estimated patented and unpatented technology amortization over the next five years is expected to be $886,998.

	Marketing and distribution agreement will commence amortization with the initial commercial production of products. Trademark and license amortization is calculated straight line over a 10 year period. The Company’s estimated amortization on trademarks and licenses over the next five years is expected to be $806 and $806 for the remaining life of those assets.

Common_Stock

Common Stock	9 Months Ended
Common Stock	Sep. 30, 2013
Notes to Financial Statements	'
Common Stock	'

	Note 6 – Common Stock

	Since its inception, the Company has issued shares of common stock as follows:

	On November 14, 2008, the Companies Directors authorized the issuance of 7,100,000 founder shares at par value of $0.001. These shares are restricted under rule 144 of the Securities Exchange Commission.
	On various days in December 2008, our Directors authorized the issuance of 1,776,100 shares of common stock at a price of $0.01 per share as fully paid and non-assessable to the subscriber. These shares are not restricted and are free trading.
	On November 15, 2010, our Directors initiated a forward stock split of 18:1 and increased the authorized shares from 100,000,000 to 250,000,000
	On December 30, 2010, the Directors approved the cancellation of 87,800,000 shares of common stock.
	On December 31, 2010, the Directors issued 15,600,000 shares in conjunction with the acquisition of certain assets, more fully described in Note 9.

	On January 10, 2011 the Company issued 300,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $300,000.

	On January 15, 2011 the Company issued 200,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $200,000.

	On March 9, 2011 the Company issued 150,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $150,000.

	On April 4, 2011 the Company issued 350,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $350,000.

	On April 7, 2011 the Company issued 200,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $200,000.

	On June 3, 2011 the Company issued 5,000 shares of common stock at a price of $0.70 per share for aggregate proceeds of $3,500.

	On July 18, 2011 the Company issued 25,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $25,000.

	On July 21, 2011 the Company issued 69,610 shares of common stock at a price of $0.20 per share for aggregate proceeds of $13,922.

	On July 24, 2011 the Company issued 40,000 shares of common stock at a price of $0.50 per share for aggregate proceeds of $20,000.

	On October 20, 2011 the Company issued 37,500 shares of common stock at a price of $0.20 per share for aggregate proceeds of $7,500

	On November 8, 2011 the Company issued 200,000 shares of common stock at a price of $0.15 per share for aggregate proceeds of $30,000.

	On December 7, 2011 the Company issued 75,000 shares of common stock at a price of $0.10 per share for services provided in the amount of $7,500.

	On December 15, 2011 the Company issued 455,180 shares of common stock at a price of $0.10 per share for aggregate proceeds of $45,518.

	On December 1, 2011 the Company issued 355,695 shares of common stock at a price of $0.20 per share for conversion of a Convertible Debenture Agreement, dated August 15,2011 for a principal amount of Fifty Thousand Euros (€50,000), which bears interest at a rate of 8.5%. The aggregate proceeds amounted to $67,513.

	On December 19, 2011 the Company issued 150,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $15,000.

	In December 2011, 5BARz AG sold 21,000 common shares with a par value of 0.01 per share, at a price of CHF 3.00 ($3.26 US) per share, for aggregate proceeds of CHF 63,000 (US – $75,840). The proceeds received have been credited to additional paid in capital in these consolidated financial statements.

	On January 12, 2012 the Company issued 300,000 shares of common stock at a price of $0.10 per share for services for aggregate proceeds of $30,000.

	On February 1, 2012 the Company issued 1,500,000 shares of common stock at a price of $0.10 per share for services for aggregate proceeds of $150,000.

	On February 1, 2012 the Company issued 50,000 shares of common stock at a price of $0.10 per share for services for aggregate proceeds of $5,000.

	On February 7, 2012 the Company issued 500,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $50,000.

	On February 29, 2012 the Company issued 100,000 shares of common stock for services at a price of $0.4799 per share for aggregate proceeds of $47,990.

	On February 29, 2012 the Company issued 200,000 shares of common stock for services at a price of $0.10 per share for aggregate proceeds of $20,000.

	On March 6, 2012 the Company issued 433,334 shares of common stock at a price of $0.12 per share for aggregate proceeds of $52,000.

	On March 7, 2012 the Company issued 150,000 shares of common stock at a price of $0.12 per share for aggregate proceeds of $18,000.

	On March 20, 2012 the Company issued 333,334 shares of common stock at a price of $0.15 per share for aggregate proceeds of $50,000.

	On March 22, 2012 the Company issued 170,000 shares of common stock at a price of $0.15 per share for aggregate proceeds of $25,500.

On March 26, 2012 the Company issued 50,000 shares of common stock at a price of $0.12 per share for aggregate proceeds of $6,000.

On March 29, 2012 the Company issued 9,000,000 shares of common stock at a price of $0.20 per share in payment to CelLynx Group, Inc. for a 60% for aggregate proceeds of $1,800,000. The shares were issued to acquire the 5BARz cellular technology rights. These consolidated financial statements do not reflect the shares as issued.

On March 29, 2012 the Company issued 1,250,000 shares of 5BARz common stock at a price of $0.20 per share for aggregate proceeds of $250,000, plus $170,000 cash, in payment to two founders of CelLynx Group Inc. for 63,412,638 common shares of CelLynx Group, Inc.

On April 2, 2012 the Company issued 250,000 shares of common stock for services, at a price of $0.12 per share for an aggregate value of $30,270.

On April 18, 2012 the Company issued 100,000 shares of common stock at a price of $0.15 per share for aggregate proceeds of $15,000.

On April 30, 2012 the Company issued 125,000 shares of common stock at a price of $0.12 per share for services for an aggregate value of $14,977.

On April 30, 2012 the Company issued 66,667 shares of common stock at a price of $0.15 per share for services for an aggregate value of $10,000.

On May 3, 2012 the Company issued 80,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $8,000.

On May 14, 2012 the Company issued 20,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $2,000.

On June 12, 2012 the Company issued 95,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $9,500.

On June 21, 2012 the Company issued 2,150,000 shares of common stock at a price of $0.10 per share for services for an aggregate value of $212,685.

On June 27, 2012 the Company issued 50,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $5,000.

On July 9, 2012 the Company issued 520,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $52,000.

On July 20, 2012 the Company issued 250,000 shares of common stock at a price of $0.20 per share for services for an aggregate value of $50,000.

On August 10, 2012 the Company issued 500,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $25,000.

On August 14, 2012 the Company issued 500,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $25,000.

On August 14, 2012 the Company issued 140,000 units at a price of $0.05 per unit for aggregate proceeds of $7,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.

On September 5, 2012 the Company issued 100,000 units at a price of $0.05 per unit for aggregate proceeds of $5,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.

On September 10, 2012 the Company issued 401,338 shares of common stock at a price of $0.0299 per share as partial conversion of a note payable in settlement of $12,000 due under that note.

On September 14, 2012 the Company issued 300,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $15,000.

On October 12, 2012 the Company issued 300,000 units at a price of $0.05 per unit for aggregate proceeds of $15,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.

On October 26, 2012 the Company issued 100,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $5,000.

On December 7, 2012 the Company issued 3,300,824 shares of common stock at a price of $0.05 per share, for services with a total value of $165,041.

On December 12, 2012 the Company issued 400,000 units at a price of $0.05 per unit for aggregate proceeds of $20,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term. On December 17, 2012 the Company issued 1,200,000 units at a price of $0.05 per unit for aggregate proceeds of $60,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term. During the quarter ended March 31, 2013 the Company entered into an amending agreement with the unit holder and agreed to cancel the shares and warrants in lieu of the issuance of a convertible debenture.

On December 31, 2012 the Company issued 2,250,000 shares for services at a price of $0.05 per share, for a total value of $112,500.

On January 25, 2013 the Company issued 100,000 shares and warrants in settlement of accounts payable for services rendered in the amount of $5,000.

On February 12, 2013 the Company issued 125,000 shares of common stock at a price of $0.06 per share as partial settlement of $7,500 due under a note payable.

On February 15, 2013 the Company issued 1,440,000 shares of common stock at a price of $0.05 per share, for services with a total value of $72,000.

On February 26, 2013 the Company issued 250,000 shares of common stock at a price of $0.04 per share, for services with a total value of $10,000.

On February 26, 2013 the Company issued 91,780 shares of common stock at a price of $0.05 per share, for services with a total value of $4,589.

On March 1, 2013 the Company issued 175,000 shares of common stock at a price of $0.05 per share, for services with a total value of $8,750.

On March 1, 2013 the Company issued 600,000 shares of common stock at a price of $0.05 per share, for aggregate proceeds of $30,000.

On March 17, 2013 the Company issued 513,827 shares of common stock at a price of $0.05 per share, for services with a total value of $25,691.

On March 31, 2013 the Company issued 100,000 shares of common stock at a price of $0.05 per share, for services with a total value of $5,000.

On various days during the period from January 1, 2013 to June 30, 2013 the Company issued 11,735,000 units at a price of $0.05 per unit for aggregate proceeds of $586,750. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.

On April 1, 2013 the Company issued 425,000 shares and warrants, with a two year term and $0.20 exercise price, in settlement of accounts payable with a total value of $21,250.

On April 10, 2013 the Company issued 600,000 shares of common stock at a price of $0.05 per share, for aggregate proceeds of $30,000.

On May 15, 2013 the Company issued 200,000 shares of common stock at a price of $0.05 per share for services with a total value of $10,000.

On May 23, 2013 the Company issued 200,000 shares and warrants, with a two year term and $0.20 exercise price, in settlement of accounts payable with a total value of $10,000.

On May 28, 2013 the Company issued 100,000 shares of common stock at a price of $0.05 per share, for services with a total value of $5,000.

On July 1, 2013 the Company issued 331,200 shares and warrants, with a two year term and $0.20 exercise price, for services with a total value of $66,240.

On various days during the period July 25, 2013 to November 18, 2013 the Company issued 27,213,904 units at a price of $0.10 per unit for an aggregate amount of $2,721,390. Of that amount, $2,116,980 was paid in cash and $604,410 was paid by way of settlement of accounts payable and notes payable. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant. The private placement includes proceeds of $1,566,980 which was raised subsequent to September 30, 2013, and is not included in the balance sheet at September 30, 2013.

Convertible_Securities

Convertible Securities	9 Months Ended
Convertible Securities	Sep. 30, 2013
Notes to Financial Statements	'
Convertible Securities	'
	Note 7 – Convertible Securities
	Convertible Promissory Notes

	5BARz International, Inc.		Unpaid		Note	Unpaid		Balance		Balance
			Note Principal		Terms	Interest & penalty		30-Sep-13		31-Dec-12
	Issue Date
	27-Feb-12		$	—	(a)	$	2,771	$	2,771	$	40,832
	3-May-12			42,500	(b)		9,380		51,880		67,131
	18-Sep-12			13,500	(c)		2,654		16,154		20,712
	3-Feb-12			30,000	(d)		112,649		142,649		207,500
	8-Jun-12			50,000	(d)		56,658		106,658		100,000
	17-Dec-12			80,000	(e)		5,032		85,032		—
	8-Jan-13			147,428	(f)		8,563		155,991		—
	Notes payable – 5BARz International Inc.		$	363,428		$	197,707	$	561,135	$	436,175


	Cellynx Group Inc.		Unpaid		Note	Unpaid		Balance		Balance
			Note Principal		Terms	Interest & penalty		30-Sep-13		31-Dec-12
	Issue Date
	November. 10, 2007		$	262,356	(g)	$	61,844	$	324,200	$	316,693
	5-Apr-11			50,000	(h)		34,962		84,962		98,613
	5-Jan-12			50,000	(i)		31,948		81,948		80,438
	24-May-12			19,500	(j)		4,588		24,088		42,433
	12-Sep-12			12,500	(k)		1,049		13,549		19,202
	Notes payable Cellynx Group, Inc.		$	394,356		$	134,391	$	528,747	$	557,379
	Total		$	757,784		$	332,098	$	1,089,882	$	993,554


		(a)	On February 27, 2012, 5BARz International Inc., completed a transaction pursuant to a Promissory Note agreement (the “February 27, 2012 Note”), through which the Company borrowed $37,500. The Note bears interest at a rate of 8%, and is due on November 29, 2012, (the “Due Date”). The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 55% of the average of the three lowest closing bid prices for the Company’s common stock for a period of 10 days prior to the date of notice of conversion. On September 10, 2012, the Company redeemed $12,000 payable on that note, by the issuance of 401,338 common shares at a price of $0.0299 per share. On January 4, 2013 the Company repaid $25,000 leaving a balance due of $2,771. That amount was paid in full on October 11, 2013 and the note was cancelled.
		(b)	On May 3, 2012, 5BARz International Inc., completed a transaction pursuant to a Promissory Note agreement (the “May 3, 2012 Note”), through which the Company borrowed $42,500. The proceeds were received by the Company on May 24, 2012. The Note bears interest at a rate of 8%, and is due on February 3, 2013, (the “Due Date”). The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at the option of the holder at a variable conversion price equal to 55% of the average of the three lowest closing bid prices for the Company’s common stock for a period of 10 days prior to the date of notice of conversion. The balance due under the note with accrued interest on September 30, 2013 was $51,880. That amount was paid in full on October 11, 2013 and the note was cancelled.

		(c)	On September 18, 2012, the Company completed a transaction pursuant to a Promissory Note agreement (the “September 18, 2012 Note”), through which the Company borrowed $13,500. The Note bears interest at a rate of 8%, and is due on March 17, 2013, (the “Due Date”). The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible at the option of the holder into common stock at a variable conversion price equal to 55% of the average of the three lowest closing bid prices for the Company’s common stock for a period of 10 days prior to the date of notice of conversion. The amount due under the note agreement along with accrued interest on September 30, 2013 was $16,154. That amount was paid in full on October 11, 2013 and the note was cancelled.

		(d)	In January 2012, the Company negotiated potential agreements for a convertible debenture and an equity investment agreement with a private investment firm (La Jolla). On February 3, 2012 the investment firm advanced $100,000, and on June 8, 2013 they advanced $50,000 to the Company. As contemplated, the convertible debenture agreement provided that the investor could invest up to $500,000 and convert the principal and unpaid interest into a certain number of shares, 180 days from the date of the agreement. The equity investment agreement provided to Holder the right, from time to time during the term of the Agreement, to invest in the Company through the purchase of up to $5,000,000 of the Company’s Common Stock. Each purchase under this Agreement was to be made at 150% of the “Volume Weighted Average Price” (VWAP) on the day prior to the day the investment is made (the “Purchase Price”). Beginning on the date that is one hundred eighty (180) days following the Issue Date, Holder shall have the right to purchase Common Stock under this Agreement. Provided the VWAP is above $0.06, Holder shall purchase a minimum of $50,000 per month beginning two hundred ten (210) days from the Issue Date.

			On August 2, 2012 and August 13, 2012, the Company received conversion notices that materially conflict with the parties’ negotiations and the terms of the agreement. The Company offered to repay the amounts invested along with accrued interest and additional share compensation, but arrived at no settlement.

			On October 16, 2012, the investment firm filed a complaint in the federal court for the Northern District of California claiming breach of contract and seeking compensatory damages and alleged loss of profits of in excess of $2,500,000, based upon their $150,000 investment made under the putative agreements. La Jolla Cove Investors, Inc. v. 5BARz International, Inc., 3:12-CV-5333 (N.D. Cal.). On November 8, 2012, the Company filed an answer, affirmative defenses, and counterclaims, against the plaintiff. On January 3, 2013, the Company entered into a settlement agreement requiring payments in the aggregate amount of $300,000 yielding interest at 9%, and the issuance of 125,000 shares of the common stock of the Company. The Company issued the 125,000 shares on February 12, 2013. On March 13, 2013, an order granting entry of stipulated judgment was granted to La Jolla Cove Investors for payment by the Company of the $300,000 plus interest at 9%. The $300,000 along with 9% interest aggregated $319,307 and has been accrued at September 30, 2013. During the nine months ended September 30, 2013 the Company repaid $70,000, leaving a balance of $249,307 payable at September 30, 2013. Subsequent to September 30, 2013 the Company paid $50,000 on October 23, 2013 and $50,000 on November 12, 2013, leaving a residual balance due of $149,307.
		(e)	In December 2012, a shareholder purchased 1,600,000 common shares for $80,000. The Company included the shares in issued and outstanding shares as of December 31, 2012, but the investor never took possession of the shares. On January17, 2013, the security was amended to a convertible debenture with an 8% per annum yield and may be converted into common stock, 90 days after the inception of the agreement, at a price which is a 20% discount to market, but not less than $0.05 per share. During the nine month period to September 30, 2013, interest of $5,032 was accrued on the convertible debenture. In connection with the convertible debt, the Company recorded $21,440 of derivative liability as of September 30, 2013.

		(f)	On January 8, 2013 the Company entered into a convertible debenture agreement with a consultant in settlement of $147,428 payable to that consultant for services rendered. The convertible debenture yields interest at 8% per annum and may be converted into common stock, 90 days after the inception of the agreement, at a price which is a 20% discount to market, but not less than $0.05 per share. During the nine month period to September 30, 2013, interest of $8,563 was accrued on the convertible debenture. In connection with the convertible debt the Company recorded $39,332 of derivative liability as of September 30, 2013.

		(g)	On August 15, 2006, CelLynx, Inc. issued a secured promissory note (the “August 2006 Note”) for $250,000 to an unrelated entity “Holder”. On November 10, 2007, the August 2006 Note was amended (the “Amended Note”). At the date of the amendment, the Company was obligated to pay to the Holder $262,356 which represented the principal and accrued interest. In contemplation of the completion of the reverse merger, the Company and the holder reached an agreement whereby this Amended Note superseded the August 2006 Note. The principal amount of the Amended Note is $262,356, is unsecured and bears interest at 4% per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. All unpaid principal, together with any then accrued but unpaid interest, shall be due and payable upon the earlier of (i) November 9, 2010 at the written request of the holder to the Company, or (ii) when, upon or after the occurrence of an event of default. The principal amount is convertible into 4.8% of the Company shares outstanding. On August 2, 2013 the Company entered into a settlement and release agreement with the holder of the unsecured promissory note, which required a payment by the Company on or before September 15, 2013 in the amount of $27,500, for the settlement of the full amount of the note payable in the principal amount of $262,356. On October 24, 2013, the parties agreed to settle the debt by issuance of 275,000 units at a price of $0.10 per unit with each unit comprised of one (1) common share of 5BARz and one share purchase warrant at $0.30, exercisable for a period of two years. At September 30, 2013, the note payable was carried at an amount of $324,200.

		(h)	On April 5, 2011, CelLynx Group, Inc. entered into a Securities Purchase Agreement with a former director of CelLynx Group, Inc., in connection with the purchase of a Convertible Promissory Note. Pursuant to the convertible note agreement the former director loaned to CelLynx Group, Inc. the principal amount of $50,000. The Note bears interest at a rate of 8%, and was due on January 5, 2012. Pursuant to the terms of the note, the principle and accrued interest could have been converted into shares of the Company’s common stock, with the number of shares issuable determined by dividing the amount to be converted by the conversion price which is equal to 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion. On November 8, 2013, the parties agreed to settle the note principle and accrued interest by issuance of 603,780 units at a price of $0.10 per unit with each unit comprised of one (1) common share of 5BARz and one share purchase warrant at $0.30, exercisable for a period of two years. At September 30, 2013, the note payable and accrued interest was carried at an amount of $84,962.

		(i)	On January 5, 2012, CelLynx Group, Inc. issued a note in the amount of $50,000, by way of settlement of certain debts owed by the Company to Holder. The Note bears interest at a rate of 8%, and was due on July 3, 2012. Holder may convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined to be the amount obtained by dividing the amount to be converted by the conversion price which is the lesser of $0.0013 per share or 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion. On June 5, 2013 the Company entered into a settlement agreement with the holder of the convertible promissory note whereby it was agreed that provided that the Company made a payment of $35,000 on or before September 15, 2013, that the principal balance and accrued penalties and interest on the note and other accounts payable due to the creditor aggregating $170,000 will be settled in full. That cash payment was not made. On October 25, 2013 the parties agreed to settle the note principle and accrued interest and other payables aggregating by issuance of 440,000 units at a price of $0.10 per unit with each unit comprised of one (1) common share of 5BARz and one share purchase warrant at $0.30, exercisable for a period of two years. At September 30, 2013, the note payable and accrued interest was carried at an amount of $81,948.

		(j)	On May 24, 2012, CelLynx Group, Inc., completed a transaction pursuant to a Promissory Note agreement, through which the Company borrowed $37,500. The Note bears interest at a rate of 8%, and is due on November 24, 2012, (the “Due Date”). The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion. The Company redeemed $18,000 payable on that note, by the issuance of CelLynx Group, Inc. common shares. The note principle and accrued interest outstanding at September 30, 2013 was $24,088.

		(k)	On September 12, 2012, CelLynx Group, Inc., completed a transaction pursuant to a Promissory Note agreement, through which the Company borrowed $12,500. The Note bears interest at a rate of 8%, and is due on March 12, 2013, (the “Due Date”). The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion. The note was carried at $13,549 comprised of principle and interest due at September 30, 2013.

			Subsequent to year end, December 31, 2012 the Company had received a notice of default on notes entered into with the lender. Accordingly all notes to the lender had been recorded at the default amount at December 31, 2012 as the result of a cross default provision in the agreements. The Company accrued a default penalty of 50% of the notes payable as well as default interest at 22% per annum from the date of default.

Options_and_Warrants

Options and Warrants	9 Months Ended
Options and Warrants	Sep. 30, 2013
Options And Warrants	'
Options and Warrants	'
	Note 8 – Options and Warrants
	Options – 5BARz International Inc.
		Number of			Weighted Average			Average Remaining
		Options			Exercise Price			Contractual Life
	Outstanding at December 31, 2012		0		$	0
	Granted		4,000,000			0.1
	Exercised		—			—
	Cancelled		—			—
	Outstanding at September 30, 2013		4,000,000		$	0.1			2.63
	Exercisable at September 30, 2013		4,000,000		$	0.1			2.63

	On May 17, 2013 the Company established the 2013 stock incentive plan for the Company. On that date 4,000,000 stock options were issued to officers of the Company to acquire common stock at a price of $0.10 per share. The Company reports stock-based compensation under ASC 718 “Compensation – Stock Compensation”. ASC 718 requires all share-based payments to employees, including grants of employee stock options, warrants to be recognized in the consolidated financial statements based on their fair values. The Company amortizes the fair value of employee stock options on a straight-line basis over the requisite service period of the awards. The Company accounts for equity instruments issued to non-employees as compensation in accordance with the provisions of ASC 718, which require that each such equity instrument be recorded at its fair value on the measurement date, which is typically the date the services are performed. The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. At May 17, 2013, the Company measured the stock options issued at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:


			17-May-13
	Stock price		$	0.097
	Volatility			225	%
	Risk-free interest rate			0.04	%
	Dividend yield			0	%
	Expected life			3.0 years

	In addition to the stock options issued pursuant to the 2013 stock option plan as provided above, the Company granted 2,000,000 shares (valued at $160,000) to be provided to the CTO of the Company, to be vested over a period which is the sooner of (i) 12 months of engagement with the Company as CTO, or (ii) the successful completion of the beta test unit as specified in working with the Company’s collaborative partner, a multi-national wireless operator.
	At May 17, 2013, the fair value of the options were determined to be $367,925 based upon the assumption provided above. The option valuations are being amortized over vesting terms ranging from 1-3 years. The stock commitment is being amortized over a one year vesting term. For the nine months ended September 30, 2013, $135,653 was amortized to expense.
	Warrants – 5BARz International Inc.

	The following table summarizes the warrant activity to September 30, 2013:
		Number of			Weighted Average			Average Remaining
		Warrants			Exercise Price			Contractual Life
	Outstanding at December 31, 2012		2,140,000		$	0.2
	Granted		21,819,885			0.25
	Exercised		—			—
	Cancelled		1,600,000			0.2
	Outstanding at September 30, 2013		22,359,885		$	0.25			1.71
	Exercisable at September 30, 2013		22,359,885		$	0.25			1.71

	During the nine months ended September 30, 2013 the Company granted 21,819,885 warrants of which 17,194.885 were issued as part of a unit in various equity raises.
	On September 1, 2013 the Company issued 4,625,000 warrants to a consultant of the Company to acquire common stock at a price of $0.20 per share. At September 1, 2013, the Company measured the warrants issued at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:
			1-Sep-13
	Stock price		$	0.092
	Volatility			240	%
	Risk-free interest rate			0.04	%
	Dividend yield			0	%
	Expected life			2.0 years

	At September 1, 2013, the fair value of the 4,625,000 warrants were determined to be $370,979 based upon the assumption provided above. For the period ended September 30, 2013, $370,979 was charged as an expense.

	Options – CelLynx Group, Inc.

	At September 30, 2013, CelLynx Group Inc. has the following Options outstanding;

	The number and weighted average exercise prices of all options and warrants exercisable as of September 30, 2013, are as follows:

	CelLynx Group, Inc. - Options Exercisable

							Weighted average				Weighted average remaining contract life
			Options				exercise price				Weighted average remaining contract life
	Opening at December 31, 2012			6,400,000			$	0.0008				0
	Granted			65,000,000			$	0.0002				4.5
	Expired			6,400,000				0.0008				0
	Outstanding at September 30, 2013			65,000,000			$	0.0002				4.5

	On August 28, 2013, the Board of Directors of CelLynx Group, Inc. extended the terms and granted additional options to various former employees and directors. The options were expiring as a result of the termination of term of employment of each option holder. The Company has re-valued those options as a result of the significant change in terms thereof. At August 28, 2013, the Company measured the options issued at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:


		28-Aug-13
Stock price		$	0.0002
Volatility			479	%
Risk-free interest rate			0.04	%
Dividend yield			0	%
Expected life			4.5 years

The fair value of the options to purchase 65,000,000 shares of CelLynx common stock were determined to be $4,500 based upon the assumption provided above. The option valuations are being fully vesting at the date of issuance. For the period ended September 30, 2013, $4,500 was amortized to expense.
Warrants – CelLynx Group, Inc.

The following table summarizes the warrant activity to September 30, 2013:
		Number of				Weighted Average				Average Remaining
		Warrants				Exercise Price				Contractual Life
Outstanding at December 31, 2012			5,930,000			$	0.79
Granted
Exercised			—				—
Expired			1,430,000				0.1
Outstanding at September 30, 2013			4,500,000			$	0.96				1.4
Exercisable at September 30, 2013			4,500,000			$	0.96				1.4

Related_Party_Transaction

Related Party Transaction	9 Months Ended
Related Party Transaction	Sep. 30, 2013
Notes to Financial Statements	'
Related Party Transaction	'
	Note 9 - Related party transactions
	On December 30, 2010 the Company acquired by way of an assignment agreement all right title and interest in a set of agreements from a Company of which the President and Director is also the President and Director of the reporting Company. The proceeds to be paid for that assignment agreement was comprised of a note payable in the amount of $370,000, and the issuance of 15,600,000 shares of common stock. That amount was paid in full along with interest at a rate of 5% per annum. That note payable was paid in full by June 30, 2012. At September 30, 2013 the Company had a balance due to the related party in the amount of $472 (December 31, 2012 - $19,850).

Commitments

Commitments	9 Months Ended
Commitments	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments	'
	Note 10 – Commitments

	Lease Agreements

	On July 1, 2013, the Company entered into an office lease agreement for an office facility in New York, NY. The office lease provides for a monthly payment of $1,371. The lease term is 15 months ending September 30, 2014.

	On July 24, 2013 the Company entered into a lease agreement in San Diego, which commenced on October 1, 2013. Pursuant to the terms of that lease, the Company s committed over a period of 39 months to minimum lease payments of $281,154.

Litigation

Litigation	9 Months Ended
Litigation	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Litigation	'
	Note 11 - Litigation

	Prior to the Company’s investment in CelLynx, on November 8, 2011 CelLynx Group, Inc. was a Defendant in an action brought by Dophinshire L.P., a California Limited Partnership(“the Plaintiff”) regarding its office space in Mission Viejo, CA. That action has since been dismissed. On November 8, 2011, plaintiff brought suit against the Company for unlawful detainer of offices located at 25910 Acero, Suite 370, Mission Viejo, CA 92691 pursuant to a lease agreement, seeking an unspecified amount of damages not to exceed $25,000. The Company has engaged in settlement negotiations with the plaintiff and management expected to settle has since, by agreement, vacated the leased premises and continues to negotiate a payout of past due rent and penalties and has moved the general office to 4014 Calle Isabella, San Clemente, CA 92672. Past due rents have been included in accounts payable at September 31, 2013 and are subject to adjustments based on the outcome of negotiation.


	On August 27, 2012, an action was brought against CelLynx Inc. and Does 1-10, in the Superior Court of California, El Dorado County, Case No. PCL20120700. On August 27, 2012, CSS Properties brought suit against CelLynx, Inc. for unlawful detainer of offices located at 5047 Robert J Matthews Parkway, El Dorado Hills, CA 95762 pursuant to a lease agreement, seeking damages of $24,699, legal fees of $3,000 and late charges of $2,041. The Company had by agreement, vacated the leased premises and continues to negotiate a payout of past due rent and penalties. Past due rents have been included in accounts payable at September 30, 2013 and are subject to adjustments based on the outcome of negotiation.

	Prior to the Company’s investment in CelLynx, on July 19, 2010 certain claims for unpaid wages were filed against CelLynx. Judgments were obtained commencing in August 2011 for back wages by some of its former employees. Some of those claims have been partially paid and others were expected to be paid in the normal course of business or were to be otherwise defended. Those claims have now been incorporated into California Labor Commission awards in favor of those former employees. Those awards total approximately $263,023 depending on interest charges. It is the intention of Cellynx, Inc. to pay these amounts when proceeds are available.

	On October 16, 2012, a complaint was filed in the federal court for the Northern District of California against 5BARz International Inc. and Does 1 - 10, claiming breach of contract and seeking compensatory damages and alleged loss of profits of in excess of $2,500,000, based upon a $150,000 investment made by LA Jolla Cove Investors under certain putative agreements. La Jolla Cove Investors Inc. v. 5BARz International, Inc., 3:12-CV-5333 (N.D. Cal.). On January 3, 2013, the Company and La Jolla Cove Investors, Inc. entered into an agreement for the settlement of the lawsuit for proceeds of $300,000 plus accrued interest from the date of the settlement agreement at a rate of 9%, plus the delivery of 125,000 shares of the common stock of the Company.

	On January 13, 2013 a stipulation dismissing action without prejudice and without award of attorney’s fees or costs was entered. The Company issued the 125,000 shares but was unable to meet the payment schedule as provided in the settlement agreement. On March 8, 2013 as a result of the default, La Jolla Cove was awarded a judgment in the amount of $300,000 plus accrued interest at a rate of 9% from the date of the settlement agreement plus 125,000 shares which have been issued. On May 22, 2013 the Company made an initial repayment on the loan in the amount of $10,000. During the quarter ended September 30, 2013 the Company repaid $70,000, leaving a balance of $249,307 payable at September 30, 2013. Subsequent to September 30, 2013 the Company paid $50,000 on October 23, 2013 and $50,000 on November 12, 2013, leaving a residual balance due of $149,307.

	On March 22, 2013 a complaint was filed in the Supreme Court of the State of New York, County of Nassau against 5BARz International Inc, Daniel Bland and James Vandeberg, by Asher Enterprises, Inc. claiming repayment of three Promissory notes in the principal amount of $81,000, penalties and interest. Asher Enterprises, Inc. vs. 5BARz International Inc., Daniel Bland and James Vandeberg 13-003472(County of Nassau). The claims allege that damages in the amount of the greater of; (i) 200% x $81,000, the remaining outstanding principal amount of the Note, together with accrued and unpaid interest in the unpaid principal amount of the Notes, plus default interest; or (ii) the “parity value” of the “default amount” paid in shares as defined in the terms of the agreements. On October 14, 2013 the lawsuit was settled by payment of $70,805.30, paid by the defendant on October 15, 2013.

	On March 29, 2011, the Company’s subsidiary CelLynx Group, Inc. received a Cease Trading Order from the British Columbia Securities Commission (BCSC) alleging that the Company is in violation of the British Colombia reporting requirements. The BCSC assumed that since two the Company's Directors were domiciled in BC that the company is controlled out of BC and therefore subject to its reporting requirements. The Company denies that premise and is appealing the issuance of the CTO. The effect of the cease trade order was that Cellynx Group, Inc. shares could not be traded by British Columbia residents. At September 30, 2013, the Company’s sole Director is not domiciled in BC.

	In addition to the above, the Company may become involved in legal proceedings in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

Subsequent_Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2013
Notes to Financial Statements	'
Subsequent Events	'
	Note 12 – Subsequent events

	Issuance of Common Stock

	During the period from October 1, 2013 to November 12, 2013, the Company sold the following equity securities;

	On November 18, 2013 the Company completed a private placement in the aggregate amount of $2,721,390 by the issuance of 27,213,904 units at a price of $0.10 per unit for aggregate cash proceeds of $2,116,980 and shares issued to settle accounts payable and notes payable of $604,410. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.30 per share acquired, with a two year warrant term. The cash proceeds received on this private placement after September 30, 2013 was $1,566,980 and the debt component settled after September 30, 2013 was $596,541.

	Settlement of Debts

	On September 30, 2013, the Company entered into an agreement with CelLynx Group, Inc. for the transfer of liabilities and notes payable in the aggregate amount of $1,440,768 to the Company under the Line of Credit agreement established between the Companies. During the period October 1 to November 18, 2013, the Company settled those liabilities by way of the issuance of $511,957 in securities comprised of the issuance of 5,119,574 units, at a price of $0.10 per unit. Each unit is comprised of one share and one share purchase warrant to acquire a share at a price of $0.30 per unit for a period of 2 years. In addition the Company settled accounts payable in the amount of $92,453 for units on the same terms. As a result, the Company incurred a gain of $928,811 on the settlement of debts.

	Lease Agreement

	On October 1, 2013 the Company commenced a lease agreement for a 4,337 square foot, Research and Development facility in San Diego, California. The facility lease provides for a monthly payment of $8,023. The lease term is 39 months ending December 31, 2016. The future minimum lease payments are $312,897 over the term of the lease.

	Line of Credit Agreement

	On September 30, 2013 5BARz International Inc. extended the terms of the line of credit agreement that had been entered into with CelLynx Group, Inc., prior to the maturity date of that agreement of October 5, 2013. In conjunction with the extension of that agreement, CelLynx transferred liabilities and notes payable in the aggregate amount of $1,440,768 to the Company under the Line of Credit agreement. This resulted in an aggregate funding under the terms of the Line of Credit agreement of $2,504,106 to date. The terms of the revised line of credit agreement remained unchanged except that the conversion rights were amended to be at 51% to market, and that the conversion privileges may be amended when the Company CelLynx Group, Inc. no longer have further 3^rd party convertible notes


	Pro-Forma Financial Information

	The financial results reflected in the balance sheet of the Company at September 30, 2013, do not reflect certain debt settlements or the completion of the private placement which was in process at September 30, 2013 and referred to above. The below pro-forma Balance Sheet, integrates the completion of the private placement and debt settlement agreements which were subsequent to September 30, 2013.


	5BARz INTERNATIONAL INC. AND SUBSIDIARIES
	( A Development Stage Company)
	CONDENSED CONSOLIDATED PRO-FORMA BALANCE SHEETS
	(Unaudited)
			September 30,			Adjustments		September 30,
			2013					2013
	ASSETS							Pro-Forma
	CURRENT ASSETS:
	Cash		$	143,754		(i) 1,566,980		$	1,710,734
	Prepaid expenses and deposits			61,075					61,075
	TOTAL CURRENT ASSETS			204,829					1,771,809

	FIXED ASSETS:
	Equipment, net			7,015					7,015
	OTHER ASSETS:
	Intangible assets			3,387,406					3,387,406
	Goodwill			1,140,246					1,140,246
	Total other assets			4,527,652					4,527,652
	TOTAL ASSETS		$	4,739,496				$	6,306,476

	LIABILITIES AND STOCKHOLDERS' EQUITY

	CURRENT LIABILITIES:
	Accounts payable and accrued expenses		$	2,562,262		(ii) (1,018,823)		$	1,543,439
	Due to escrow agent			52,321					52,321
	Accrued derivative liabilities			60,772					60,772
	Notes payable (net of discount)			1,089,882		(iii) (514,398)			575,484
	TOTAL CURRENT LIABILITIES			3,765,237					2,232,016
	Related party loans			472					472

	TOTAL LIABILITIES			3,765,709					2,232,488

	STOCKHOLDERS' EQUITY
	Common stock, $.001 par value, 250,000,000 shares authorized; 160,117,625 shares issued and outstanding as of September 30, 2013 on a pro-forma basis			138,404		21,714			160,118
	Capital in excess of par value			5,179,130		2,149,676			7,328,806
	Deficit accumulated during the development stage			(4,989,290	)	(iv) 928,811			(4,060,479	)
	Accumulated Other Comprehensive Income			27,250					27,250
Non-controlling interest			618,293					618,293
Total stockholders' equity			973,787					4,073,988
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$	4,739,496				$	6,306,476

	(i)	Private placement proceeds received subsequent to September 30, 2012 - $1,566,980
	(ii)	Settlement of accounts payable for units $1,018,823
	(iii)	Settlement of notes payable for units $514,398
	(iv)	Gain on settlement of debts - $928,811

Summary_of_significant_account1

Summary of significant accounting policies (Policies)

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Basis of Presentation

Basis of presentation

Use of estimates

Intangible assets

Goodwill

Foreign currency translation

Fair value of financial instruments

•

Level 1. Quoted prices in active markets for identical assets or liabilities.

•

Level 3. Significant unobservable inputs that cannot be corroborated by market data.

Consolidated

Quoted Prices in Active Markets for Identical Assets or Liabilities

Quoted Prices for Similar Assets or Liabilities in Active Markets

Significant

Balance Sheet

(Level 1)

(Level 2)

Unobservable

Inputs

(Level 3)

Derivative Liabilities:

30-Sep-13

60,772

—

60,772

31-Dec-12

—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

30-Sep-13

Beginning balance

—

Change in fair value of derivative liabilities

60,772

Ending balance

60,772

30-Sep-13

Stock price

0.14

Volatility

240

Risk-free interest rate

0.04

Dividend yield

Expected life

0.002 years

As of September 30, 2013 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.

Derivative Instruments

Derivative instruments

Net loss per share

Stock-based Compensation

Stock Based Compensation

Reclassifications

Recent accounting pronouncements

Summary_of_Accounting_Policies

Summary of Accounting Policies (Tables)	9 Months Ended
Summary of Accounting Policies (Tables)	Sep. 30, 2013
Summary Of Accounting Policies Tables	'
Fair Value of Financial instruments Assets and Liabilities	'
		Consolidated			Quoted Prices in Active Markets for Identical Assets or Liabilities		Quoted Prices for Similar Assets or Liabilities in Active Markets		Significant
		Balance Sheet			(Level 1)		(Level 2)		Unobservable
									Inputs
									(Level 3)
	Derivative Liabilities:
	30-Sep-13	$	60,772		$	—	$	—	$	60,772
	31-Dec-12	$	—		$	—	$	—	$	—
Level 3 financial liabilities that are measured at fair value on a recurring basis	'
		30-Sep-13
	Beginning balance	$	—
	Change in fair value of derivative liabilities		60,772
	Ending balance	$	60,772
Fair Value of Financial instruments Black-Scholes option pricing models	'
		30-Sep-13
	Stock price	$	0.14
	Volatility		240	%
	Risk-free interest rate		0.04	%
	Dividend yield		0	%
	Expected life		0.002 years

Acquisition_of_CelLynx_Group_I1

Acquisition of CelLynx Group, Inc. (Tables)	9 Months Ended
Acquisition of CelLynx Group, Inc. (Tables)	Sep. 30, 2013
Notes to Financial Statements	'
Acquistion of Cellynx Group, Inc.	'
	i.	Cash consideration paid		$	170,000
	ii.	1,250,000 common shares of the registrant issued at a market price of $0.20 per share			250,000
	iii.	Redemption of convertible debt for 350 million shares of CelLynx Group Inc. common stock			455,000	(a)
	Fair market value of consideration paid			$	875,000
Assets and Liabilities recognized at acquisition date	'
	Description	Net book value of CelLynx Group, Inc. consolidated assets and liabilities				Acquisition			Valuation attributed to assets acquired
	Description					Adjustments (i) (ii)			Valuation attributed to assets acquired
	Current assets	$	3,260						$	3,260
	Patented and unpatented technology, trademarks, and license		44,718			$	1,155,282	(ii)		1,200,000
	Investment in 5BARz (iii)		1,800,000							1,800,000
	Furniture and equipment		2,113							2,113
	Accounts payable and accruals		(1,752,628	)						(1,752,628	)
	Notes payable (net of discount)		(403,076	)						(403,076	)
	Accrued interest		(62,250	)						(62,250	)
	Derivative liability		(5,495,425	)			5,026,093	(i)		(469,332	)
	LOC payable – 5BARz (net)		(586,525	)			586,525	(i)		—
	Fair value non-controlling interest						(583,333	)		(583,333	)
	Totals	$	(6,449,813	)		$	6,184,567			(265,246	)
	Goodwill									1,140,246
	Purchase price								$	875,000

Convertible_Securities_Tables

Convertible Securities (Tables)	9 Months Ended
Convertible Securities (Tables)	Sep. 30, 2013
Convertible Securities Tables	'
Convertible Promissory Note	'
	Convertible Promissory Notes

	5BARz International, Inc.	Unpaid		Note	Unpaid		Balance		Balance
		Note Principal		Terms	Interest & penalty		30-Sep-13		31-Dec-12
	Issue Date
	27-Feb-12	$	—	(a)	$	2,771	$	2,771	$	40,832
	3-May-12		42,500	(b)		9,380		51,880		67,131
	18-Sep-12		13,500	(c)		2,654		16,154		20,712
	3-Feb-12		30,000	(d)		112,649		142,649		207,500
	8-Jun-12		50,000	(d)		56,658		106,658		100,000
	17-Dec-12		80,000	(e)		5,032		85,032		—
	8-Jan-13		147,428	(f)		8,563		155,991		—
	Notes payable – 5BARz International Inc.	$	363,428		$	197,707	$	561,135	$	436,175


	Cellynx Group Inc.	Unpaid		Note	Unpaid		Balance		Balance
		Note Principal		Terms	Interest & penalty		30-Sep-13		31-Dec-12
	Issue Date
	November. 10, 2007	$	262,356	(g)	$	61,844	$	324,200	$	316,693
	5-Apr-11		50,000	(h)		34,962		84,962		98,613
	5-Jan-12		50,000	(i)		31,948		81,948		80,438
	24-May-12		19,500	(j)		4,588		24,088		42,433
	12-Sep-12		12,500	(k)		1,049		13,549		19,202
	Notes payable Cellynx Group, Inc.	$	394,356		$	134,391	$	528,747	$	557,379
	Total	$	757,784		$	332,098	$	1,089,882	$	993,554

Options_and_Warrants_Tables

Options and Warrants (Tables)	9 Months Ended
Options and Warrants (Tables)	Sep. 30, 2013
Options And Warrants Tables	'
Options- 5BARz International Inc.	'
		Number of			Weighted Average			Average Remaining
		Options			Exercise Price			Contractual Life
	Outstanding at December 31, 2012		0		$	0
	Granted		4,000,000			0.1
	Exercised		—			—
	Cancelled		—			—
	Outstanding at September 30, 2013		4,000,000		$	0.1			2.63
	Exercisable at September 30, 2013		4,000,000		$	0.1			2.63
Weighted Average Exercise Price of all Options	'

			17-May-13
	Stock price		$	0.097
	Volatility			225	%
	Risk-free interest rate			0.04	%
	Dividend yield			0	%
	Expected life			3.0 years
Warrants - 5BARz International Inc.	'
		Number of			Weighted Average			Average Remaining
		Warrants			Exercise Price			Contractual Life
	Outstanding at December 31, 2012		2,140,000		$	0.2
	Granted		21,819,885			0.25
	Exercised		—			—
	Cancelled		1,600,000			0.2
	Outstanding at September 30, 2013		22,359,885		$	0.25			1.71
	Exercisable at September 30, 2013		22,359,885		$	0.25			1.71
Significant Assumptions and valuation methods - 5BARz International Inc.	'
			1-Sep-13
	Stock price		$	0.092
	Volatility			240	%
	Risk-free interest rate			0.04	%
	Dividend yield			0	%
	Expected life			2.0 years
Options-CelLynx Group, Inc.	'
							Weighted average			Weighted average remaining contract life
			Options				exercise price			Weighted average remaining contract life
	Opening at December 31, 2012			6,400,000			$	0.0008			0
	Granted			65,000,000			$	0.0002			4.5
	Expired			6,400,000				0.0008			0
	Outstanding at September 30, 2013			65,000,000			$	0.0002			4.5
Significant Assumptions and valuation methods - CelLynx Group, Inc.	'

			28-Aug-13
	Stock price		$	0.0002
	Volatility			479	%
	Risk-free interest rate			0.04	%
	Dividend yield			0	%
	Expected life			4.5 years
Warrants - CelLynx Group, Inc.	'
			Number of				Weighted Average			Average Remaining
			Warrants				Exercise Price			Contractual Life
	Outstanding at December 31, 2012			5,930,000			$	0.79
	Granted
	Exercised			—				—
	Expired			1,430,000				0.1
	Outstanding at September 30, 2013			4,500,000			$	0.96			1.4
	Exercisable at September 30, 2013			4,500,000			$	0.96			1.4

Subsequent_Events_Tables_USD

Subsequent Events (Tables) (USD $)	9 Months Ended
Subsequent Events (Tables) (USD $)	Sep. 30, 2013
Subsequent Events Tables Usd	'
Pro-forma Financial Information	'

	5BARz INTERNATIONAL INC. AND SUBSIDIARIES
	( A Development Stage Company)
	CONDENSED CONSOLIDATED PRO-FORMA BALANCE SHEETS
	(Unaudited)
		September 30,			Adjustments	September 30,
		2013				2013
	ASSETS					Pro-Forma
	CURRENT ASSETS:
	Cash	$	143,754		(i) 1,566,980	$	1,710,734
	Prepaid expenses and deposits		61,075				61,075
	TOTAL CURRENT ASSETS		204,829				1,771,809

	FIXED ASSETS:
	Equipment, net		7,015				7,015
	OTHER ASSETS:
	Intangible assets		3,387,406				3,387,406
	Goodwill		1,140,246				1,140,246
	Total other assets		4,527,652				4,527,652
	TOTAL ASSETS	$	4,739,496			$	6,306,476

	LIABILITIES AND STOCKHOLDERS' EQUITY

	CURRENT LIABILITIES:
	Accounts payable and accrued expenses	$	2,562,262		(ii) (1,018,823)	$	1,543,439
	Due to escrow agent		52,321				52,321
	Accrued derivative liabilities		60,772				60,772
	Notes payable (net of discount)		1,089,882		(iii) (514,398)		575,484
	TOTAL CURRENT LIABILITIES		3,765,237				2,232,016
	Related party loans		472				472

	TOTAL LIABILITIES		3,765,709				2,232,488

	STOCKHOLDERS' EQUITY
	Common stock, $.001 par value, 250,000,000 shares authorized; 160,117,625 shares issued and outstanding as of September 30, 2013 on a pro-forma basis		138,404		21,714		160,118
	Capital in excess of par value		5,179,130		2,149,676		7,328,806
	Deficit accumulated during the development stage		(4,989,290	)	(iv) 928,811		(4,060,479	)
	Accumulated Other Comprehensive Income		27,250				27,250
	Non-controlling interest		618,293				618,293
	Total stockholders' equity		973,787				4,073,988
	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	4,739,496			$	6,306,476

Organization_and_Basis_of_Repo

Organization and Basis of Reporting (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
	5BARz AG	CelLynx Group, Inc.
Business Acquisition [Line Items]	'	'
Agreement date	6-Nov-11	29-Mar-12
Acquired interest	94.30%	'
Ownership in Entity	'	'CeLlynx Inc.
Percentage Owned	60.00%	100.00%

Going_concern_Details

Going concern (Details) (USD $)	59 Months Ended
Going concern (Details) (USD $)	Sep. 30, 2013
Going Concern Details	'
Net loss	$4,975,662
Negative Cash Flows	2,451,387
Accumulated Deficit	$4,989,290

Summary_of_Accounting_Policies1

Summary of Accounting Policies (Details) (USD $)	9 Months Ended
Summary of Accounting Policies (Details) (USD $)	Sep. 30, 2013
Derivative Liabilities	$60,772
Level 3	'
Level 3 Valuation Methodolgy	'
Stock Price	$0.14
Expected volatility	240.00%
Risk-free Interest	0.04%
Annual Dividend Yield	0.00%
Exepected Life (years)	'2 days

Acquisition_of_CelLynx_Group_I2

Acquisition of CelLynx Group, Inc.Description (Details Narrative) (USD $)	1 Months Ended	0 Months Ended	3 Months Ended
	Mar. 29, 2012	Jan. 07, 2011	Mar. 29, 2012
	Mar. 29, 2012	CelLynx Group, Inc.	CelLynx Group, Inc.
Common Stock recieved from CelLynx Group, Inc.	'	63,412,638	'
Purchase Price for common stok of CelLynx Group, Inc.	'	$634,126	'
Cash consideration paid	170,000	170,000	'
Common Share of the registrant issued	'	1,250,000	'
Amount of credit facility converted to capital stock of CelLynx Group, Inc.	'	'	$73,500
Amount of Shares of CelLynx Group, Inc. resulting from conversion of credit facility	'	'	350,000,000

Investment_in_CelLynx_Group_In

Investment in CelLynx Group, Inc. (Details) (USD $)	1 Months Ended
Investment in CelLynx Group, Inc. (Details) (USD $)	Mar. 29, 2012
Business Combinations [Abstract]	'
Cash consideration paid	$170,000
1,250,000 common shares of the registrant issued at a market price of $0.20 per share	250,000
Redemption of convertible debt for 350 million shares of Cellynx Group Inc. common stock	455,000
Fair market value of consideration paid	$875,000

Investment_in_CelLynx_Group_In1

Investment in CelLynx Group, Inc. (Details) (Parenthetical) (USD $)	1 Months Ended
	Mar. 29, 2012
Common Stock For Cellynx	'
Common Share of the registrant issued	1,250,000
Common Stock recieved from Cellynx Group, Inc.	63,412,638
Common Stock	'
Price Per Unit	0.2

Investment_in_CelLynx_Group_In2

Investment in CelLynx Group, Inc. - Assets and Liabilites recognized (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Mar. 29, 2012	Mar. 29, 2012	Mar. 29, 2012
	Sep. 30, 2013	Dec. 31, 2012	Net book Value of Cellynx	Adjustments	Valuation attributed to assets acquired
Current assets	'	'	$3,260	'	$3,260
Patents, trademarks, and license	'	'	44,718	1,155,282	1,200,000
Investment in 5BARz	'	'	1,800,000	'	1,800,000
Furniture and equipment	'	'	2,113	'	2,113
Accounts payable and accruals	'	'	-1,756,628	'	-1,756,628
Notes payable (net of discount)	'	'	-403,076	'	-403,076
Accrued Interest	'	'	-62,250	'	-62,250
Derivative liability	'	'	-5,495,425	-5,026,093	-469,332
LOC payable-5BARz (net)	'	'	-586,525	-586,525	0
Fair value non-controlling interest	'	'	'	-583,333	-583,333
Totals	'	'	-6,449,813	6,184,567	-265,246
Goodwill	1,140,246	1,140,246	'	'	1,140,246
Purchase price	'	'	'	'	$875,000

Acquisition_of_CelLynx_Group_I3

Acquisition of CelLynx Group, Inc. (Details Narrative) (CelLynx Group, Inc., USD $)	0 Months Ended
	21-May-13	15-May-12	Apr. 13, 2012
CelLynx Group, Inc.	'	'	'
Conversion of debt	$9,375	$58,500	$7,700
Common Stock Recieved, share	375,000,000	390,000,000	51,333,333

Investment_in_5BARz_AG_Details

Investment in 5BARz AG (Details Narrative) (5BARz AG, USD $)	0 Months Ended	9 Months Ended
	Oct. 06, 2011	Sep. 30, 2013
5BARz AG	'	'
Subsidiary or Equity Method Investee [Line Items]	'	'
5BARz AG Common stock issued, shares	10,000,000	'
5BARz AG Common stock issued held by company, shares	5,100,000	9,458,000
5BARz AG Common stock issued held by officers and a consultant, shares	450,000	'
5BARz AG Common stock in escrow, shares	4,450,000	'
5BARz AG Common stock, Par Value	'0.01 CHF	'0.01 CHF
Common Stock Sold, in shares	'	122,000
Proceeds of Common Stock	$108,752	$372,728
Acquired interest	'	94.30%

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Intangible Assets, Gross	$3,387,406	$3,387,406
Accumulated amortization	'	'
Intangibles Assets, net	3,387,406	3,387,406
Patented and unpatented technology	'	'
Intangible Assets, Gross	3,015,794	3,015,794
Marketing and distribution agreement	'	'
Intangible Assets, Gross	370,000	370,000
Trademarks	'	'
Intangible Assets, Gross	264	264
License rights	'	'
Intangible Assets, Gross	$1,348	$1,348

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	12 Months Ended
Intangible Assets (Details Narrative) (USD $)	Dec. 31, 2013
Patented and unpatented technology	'
Life of amortization	'5 years
Amortization over the next five years	$866,998
Trademarks	'
Life of amortization	'5 years
Amortization over the next five years	806
Amortization thereafter	$806
Maximum	'
Life of amortization	'20 years
Minimum	'
Life of amortization	'10 years

Cumulative_Sales_of_Stock_2008

Cumulative Sales of Stock 2008-2010 (Details)	Nov. 13, 2008	Dec. 31, 2010	Dec. 31, 2008	Nov. 30, 2010
Cumulative Sales of Stock 2008-2010 (Details)	Founders Shares	Common Stock	Common Stock	Stock Split
Issuance of restricted common stock/founders shares	7,100,000	'	1,776,100	'
Forward stock split	'	'	'	18
Authorized Shares-before stock split	'	'	'	100,000,000
Authorized Shares-After Stock split	'	'	'	250,000,000
Cancellation of Common Stock, shares	'	87,800,000	'	'
Common stock issued forAcquistions (in shares)	'	15,600,000	'	'

Cumulative_Sales_of_Stock_2011

Cumulative Sales of Stock 2011 (Details) (USD $)

3 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2011

Dec. 19, 2011

Dec. 15, 2011

Dec. 07, 2011

Nov. 08, 2011

Oct. 20, 2011

Jul. 24, 2011

Jul. 21, 2011

Jul. 18, 2011

Jun. 03, 2011

Apr. 07, 2011

Apr. 04, 2011

Mar. 09, 2011

Jan. 15, 2011

Jan. 10, 2011

Dec. 31, 2011

Sep. 30, 2013

Conversion Of Convertible Debenture

Common Stock

5BARz

Issuance of common stock (in shares)

150,000

455,180

75,000

200,000

37,500

40,000

69,610

25,000

5,000

200,000

350,000

150,000

200,000

300,000

21,000

Issuance of common stock

$15,000

$45,581

$7,500

$30,000

$7,500

$20,000

$14,000

$25,000

$3,000

$200,000

$350,000

$150,000

$200,000

$300,000

$75,840

Conversion of Convertible Debenture Agreement (in shares)

335,695

Conversion of Convertible Debenture Agreement (Euro's)

$67,513

Price Per Unit

$0.10

$0.15

$0.20

$0.50

$0.20

$0.70

$3.26

Cumulative_Sales_of_Stock_2012

Cumulative Sales of Stock 2012 -2013 (Details) (USD $)

0 Months Ended

4 Months Ended

9 Months Ended

Jul. 03, 2013

Jun. 30, 2013

23-May-13

15-May-13

Apr. 10, 2013

Apr. 02, 2013

Mar. 31, 2013

Mar. 17, 2013

Mar. 01, 2013

Feb. 26, 2013

Feb. 15, 2013

Feb. 12, 2013

Jan. 25, 2013

Dec. 31, 2012

Dec. 17, 2012

Dec. 12, 2012

Dec. 07, 2012

Oct. 26, 2012

Oct. 12, 2012

Sep. 14, 2012

Sep. 10, 2012

Sep. 05, 2012

Aug. 14, 2012

Aug. 10, 2012

Jul. 20, 2012

Jul. 09, 2012

Jun. 27, 2012

Jun. 21, 2012

Jun. 12, 2012

14-May-12

3-May-12

Apr. 30, 2012

Apr. 18, 2012

Apr. 02, 2012

Mar. 26, 2012

Mar. 22, 2012

Mar. 20, 2012

Mar. 07, 2012

Mar. 05, 2012

Feb. 29, 2012

Feb. 07, 2012

Feb. 01, 2012

Jan. 12, 2012

Nov. 18, 2013

Sep. 30, 2013

Common Stock

Issuance of common stock (in shares)

200,000

600,000

100,000

401,338

500,000

250,000

200,000

50,000

95,000

20,000

80,000

100,000

50,000

170,000

333,334

150,000

433,334

200,000

500,000

4,540,000

Units Issued (in shares)

200,000

425,000

400,000

1,200,000

400,000

300,000

100,000

27,213,904

[1]

11,735,000

[1]

Issuance of common stock

$586,750

$10,000

$30,000

$21,250

$30,000

$20,000

$60,000

$20,000

$5,000

$15,000

$12,000

$5,000

$25,000

$52,000

$5,000

$9,500

$2,000

$8,000

$15,000

$6,000

$25,500

$50,000

$18,000

$52,000

$20,000

$50,000

$2,721,390

$227,000

Common stock issued for services (in shares)

331,200

100,000

513,827

175,000

250,000

14,400,000

100,000

2,250,000

3,300,824

2,150,000

125,000

250,000

100,000

1,500,000

300,000

Common stock issued for services

66,240

5,000

25,691

8,750

10,000

72,000

5,000

112,500

165,041

212,620

14,977

30,000

47,990

150,000

30,000

Stock Issued During Period, Shares

125,000

Stock Issued During Period

7,500

1,566,980

Price Per Unit

$0.20

$0.05

$0.04

$0.05

$0.06

$0.05

$0.03

$0.20

$0.05

$0.20

$0.10

$0.12

$0.15

$0.12

$0.15

$0.12

$0.48

$0.10

$0.05

Warrant price

0.2

0.3

0.2

Cash received for issuance of stock

2,116,980

Settlement of debt for common stock

604,410

Common Stock Additional

Units Issued (in shares)

140,000

Issuance of common stock

7,000

Common stock issued for services (in shares)

91,780

66,667

50,000

Common stock issued for services

$4,589

$10,000

$5,000

Price Per Unit

$0.05

$0.15

$0.10

[1]

Each unit is comprised of one share and one warrant to acquire a second share, with a two year warrant term.

Cumulative_Sales_of_Stock_Pric

Cumulative Sales of Stock Prices (Details) (USD $)

Nov. 18, 2013

Sep. 30, 2013

Jul. 03, 2013

15-May-13

Apr. 10, 2013

Mar. 31, 2013

Mar. 17, 2013

Mar. 01, 2013

Feb. 26, 2013

Feb. 15, 2013

Feb. 12, 2013

Dec. 31, 2012

Dec. 17, 2012

Dec. 12, 2012

Dec. 07, 2012

Oct. 26, 2012

Oct. 12, 2012

Sep. 14, 2012

Sep. 10, 2012

Sep. 05, 2012

Aug. 14, 2012

Aug. 10, 2012

Jul. 20, 2012

Jul. 09, 2012

Jun. 27, 2012

Jun. 21, 2012

Jun. 12, 2012

14-May-12

3-May-12

Apr. 30, 2012

Apr. 18, 2012

Apr. 02, 2012

Mar. 26, 2012

Mar. 22, 2012

Mar. 20, 2012

Mar. 07, 2012

Mar. 05, 2012

Feb. 29, 2012

Feb. 07, 2012

Feb. 01, 2012

Jan. 12, 2012

Sep. 30, 2013

Mar. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2011

Jun. 30, 2011

Mar. 30, 2011

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2011

Jun. 30, 2011

Mar. 30, 2011

Common Stock

Conversion Of Convertible Debenture

Common Stock for Services

Excess of Par Value

Minimum

Maximum

Common Stock

Price Per Unit

$0.10

$0.05

$0.20

$0.05

$0.04

$0.05

$0.06

$0.05

$0.03

$0.20

$0.05

$0.20

$0.10

$0.12

$0.15

$0.12

$0.15

$0.12

$0.48

$0.10

$0.20

$0.10

$3.26

$0.10

$0.05

$0.50

$0.10

$0.20

$0.70

$0.20

$0.05

$0.20

$0.15

Convertible_Promissory_Notes_D

Convertible Promissory Notes (Details) (USD $) (USD $)	9 Months Ended
Convertible Promissory Notes (Details) (USD $) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Unpaid Note Principal	$757,784	'
Unpaid Interest & penalty	332,098	'
Notes Payable	1,089,882	993,554
Note a	'	'
Issue Date	27-Feb-12	'
Unpaid Note Principal	37,500	'
Unpaid Interest & penalty	2,771	'
Notes Payable	2,771	40,832
Note b	'	'
Issue Date	3-May-12	'
Unpaid Note Principal	42,500	'
Unpaid Interest & penalty	9,380	'
Notes Payable	51,880	67,131
Note c	'	'
Issue Date	18-Sep-12	'
Unpaid Note Principal	13,500	'
Unpaid Interest & penalty	2,654	'
Notes Payable	16,154	20,712
Note d	'	'
Issue Date	3-Feb-12	'
Unpaid Note Principal	30,000	'
Unpaid Interest & penalty	112,649	'
Notes Payable	142,649	207,500
Note d-2	'	'
Issue Date	8-Jun-12	'
Unpaid Note Principal	50,000	'
Unpaid Interest & penalty	56,658	'
Notes Payable	106,658	100,000
Note e	'	'
Issue Date	17-Dec-12	'
Unpaid Note Principal	80,000	'
Unpaid Interest & penalty	5,032	'
Notes Payable	85,032	'
Note f	'	'
Issue Date	8-Jan-13	'
Unpaid Note Principal	147,428	'
Unpaid Interest & penalty	8,563	'
Notes Payable	155,991	'
5BARz	'	'
Unpaid Note Principal	363,428	'
Unpaid Interest & penalty	197,707	'
Notes Payable	$561,135	$436,175

Convertible_Promissory_Notes_D1

Convertible Promissory Notes (Details Narrative) (USD $)	9 Months Ended
Convertible Promissory Notes (Details Narrative) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Principal Amount	$757,784	'
Note Payable	1,089,882	993,554
Note a	'	'
Issue Date	27-Feb-12	'
Principal Amount	37,500	'
Date of Maturity	29-Nov-12	'
Interest Rate per annum	8.00%	'
Date	10-Sep-12	'
Note paid off	12,000	'
Common stock issued for debt	401,338	'
Date of arrangement	28-Sep-12	'
Date Due	31-Dec-12	'
Aggregate payments	25,000	'
Price per share	$0.03	'
Note Payable	2,771	40,832
Note b	'	'
Issue Date	3-May-12	'
Principal Amount	42,500	'
Date of Maturity	3-Feb-13	'
Interest Rate per annum	8.00%	'
Note Payable	51,880	67,131
Note c	'	'
Issue Date	18-Sep-12	'
Principal Amount	13,500	'
Date of Maturity	17-Mar-13	'
Interest Rate per annum	8.00%	'
Accrued interest	16,154	'
Note Payable	16,154	20,712
Note d	'	'
Issue Date	3-Feb-12	'
Principal Amount	30,000	'
Note Payable	142,649	207,500
Convertible Debenture Agreement	500,000	'
Convertible Debenture issued to investor	150,000	'
Note Receivable exchange for convertible debenture	400,000	'
Interest Rate	8.00%	'
Alleged damages	2,500,000	'
Note d-2	'	'
Issue Date	8-Jun-12	'
Principal Amount	50,000	'
Note Payable	106,658	100,000
Note e	'	'
Issue Date	17-Dec-12	'
Principal Amount	80,000	'
Interest Rate per annum	8.00%	'
Common stock issued for debt	1,600,000	'
Accrued interest	5,032	'
Note Payable	85,032	'
Derivative Liability	21,440	'
Note f	'	'
Issue Date	8-Jan-13	'
Principal Amount	147,428	'
Price per share	$0.05	'
Accrued interest	8,563	'
Note Payable	155,991	'
Derivative Liability	$39,332	'

Convertible_Promissory_Notes_D2

Convertible Promissory Notes (Details Narrative) (Parenthetical)	9 Months Ended
	Sep. 30, 2013
Note payments	'
Terms of note	'

	The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principle amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principle amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note is convertible into common stock.
Note d	'
Terms of note	'
Terms of note	On November 8, 2012, the Company filed an answer, affirmative defenses, and counterclaims, against the plaintiff. On January 3, 2013, the Company entered into a settlement agreement requiring payments in the aggregate amount of $300,000 yielding interest at 9%, and the issuance of 125,000 shares of the common stock of the Company. The Company issued the 125,000 shares on February 12, 2013. On March 13, 2013, an order granting entry of stipulated judgment was granted to La Jolla Cove Investors for payment by the Company of the $300,000 plus interest at 9%. The $300,000 along with 9% interest aggregated $319,307 and has been accrued at September 30, 2013. During the quarter ended September 30, 2013 the Company repaid $70,000, leaving a balance of $249,307 payable at September 30, 2013. Subsequent to September 30, 2013 the Company paid $50,000 on October 23, 2013 and $50,000 on November 12, 2013, leaving a residual balance due of $149,307.

Cellynx_Group_Inc_Convertibles

Cellynx Group, Inc. - Convertibles Promissory Notes (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Unpaid Note Principal	$757,784	'
UnpaidInterestPenalty	33209800.00%	'
Notes Payable	1,089,882	993,554
Note g	'	'
Issue Date	10-Nov-07	'
Unpaid Note Principal	262,356	'
UnpaidInterestPenalty	6184400.00%	'
Notes Payable	324,200	316,693
Note h	'	'
Issue Date	5-Apr-11	'
Unpaid Note Principal	50,000	'
UnpaidInterestPenalty	3496200.00%	'
Notes Payable	84,962	98,613
Note i	'	'
Issue Date	5-Jan-12	'
Unpaid Note Principal	50,000	'
UnpaidInterestPenalty	3194800.00%	'
Notes Payable	81,948	80,438
Note j	'	'
Issue Date	24-May-12	'
Unpaid Note Principal	19,500	'
UnpaidInterestPenalty	458800.00%	'
Notes Payable	24,088	42,433
Note k	'	'
Issue Date	12-Sep-12	'
Unpaid Note Principal	12,500	'
UnpaidInterestPenalty	104900.00%	'
Notes Payable	13,549	19,202
CelLnyx	'	'
Unpaid Note Principal	394,356	'
UnpaidInterestPenalty	13439100.00%	'
Notes Payable	$528,747	$557,379

Cellynx_Group_Inc_Convertibles1

Cellynx Group, Inc. - Convertibles Promissory Notes (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Face Amount	$757,784	'
Note Payable	1,089,882	993,554
Note g	'	'
Issue Date	10-Nov-07	'
Promissory Note	250,000	'
Face Amount	262,356	'
Interest Rate per annum	4.00%	'
Settlement of debt	27,500	'
Common stock issued for debt, shares	275,000	'
Price per share	$0.10	'
Note Payable	324,200	316,693
Note h	'	'
Issue Date	5-Apr-11	'
Face Amount	50,000	'
Interest Rate per annum	8.00%	'
Common stock issued for debt, shares	603,780	'
Price per share	$0.10	'
Note Payable	84,962	98,613
Note i	'	'
Issue Date	5-Jan-12	'
Face Amount	50,000	'
Interest Rate per annum	8.00%	'
Settlement of debt	170,000	'
Common stock issued for debt, shares	440,000	'
Price per share	$0.10	'
Note Payable	81,948	80,438
Note j	'	'
Issue Date	24-May-12	'
Promissory Note	37,500	'
Face Amount	19,500	'
Interest Rate per annum	8.00%	'
Settlement of debt	18,000	'
Note Payable	24,088	42,433
Note k	'	'
Issue Date	12-Sep-12	'
Face Amount	12,500	'
Interest Rate per annum	8.00%	'
Note Payable	$13,549	$19,202

Cellynx_Group_Inc_Convertibles2

Cellynx Group, Inc. - Convertibles Promissory Notes (Details Narrative) (Parenthetical)	9 Months Ended
	Sep. 30, 2013
Note g	'
Terms	'All unpaid principal, together with any then accrued but unpaid interest, shall be due and payable upon the earlier of (i) November 9, 2010 at the written request of the holder to the Company, or (ii) when, upon or after the occurrence of an event of default. The principal amount is convertible into 4.8% of the Company shares outstanding.
Note h	'
Terms	'convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined by dividing the amount to be converted by the conversion price which is equal to 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion.
Note i	'
Terms	'Holder may convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined to be the amount obtained by dividing the amount to be converted by the conversion price which is the lesser of $0.0013 per share or 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion.

Options_Exercisable_5BARz_Deta

Options Exercisable 5BARz (Details) (USD $) (5BARz, USD $)	9 Months Ended
Options Exercisable 5BARz (Details) (USD $) (5BARz, USD $)	Sep. 30, 2013
5BARz	'
Options exercisable [Abstract]	'
Beginning, Number of Options	0
Options, Granted	4,000,000
Options, Exercised	'
Options, Cancelled	'
Ending,Number of Options, outstanding and exercisable	4,000,000
Weighted Average Exercise Price	'
Weighted Average Exercise Price	$0
Weighted Average Exercise Price, Granted	$0.10
Weighted Average Exercise Price, Exercised	'
Weighted Average Exercise Price, Cancelled	$0
Weighted Average Exercise Price	$0.10
Weighted Average Remaining Contractual Life	'2 years 6 months 3 days

Options_and_Warrants_5BARz_Det

Options and Warrants 5BARz (Details) (5BARz, USD $)	0 Months Ended	1 Months Ended
Options and Warrants 5BARz (Details) (5BARz, USD $)	Sep. 01, 2013	17-May-13
5BARz	'	'
Stock Price	$0.09	$0.10
Expected volatility	240.00%	225.00%
Risk-free Interest	0.04%	0.04%
Annual Dividend Yield	0.00%	0.00%
Exepected Life (years)	'2 years	'3 years
Stock commitment, shares	4,625,000	2,000,000
Fair value of stock options	$370,979	$367,925
Share price	$0.20	$0.08
Stock options commitment expense	$370,979	$135,653

Warrant_Activity_5BARz_Interna

Warrant Activity - 5BARz International Inc. (Details) (USD $) (5BARz, USD $)	9 Months Ended
	Sep. 30, 2013
5BARz	'
Warrant Activity	'
Outstanding at December 31, 2012, Number of Warrants	2,140,000
Granted, Number of shares	21,819,885
Cancelled, Number of shares	1,600,000
Outstanding and exercisable, Number of Warrants	22,359,885
Weighted Average Exericse Price	'
Outstanding at December31, 2012	$0.20
Granted, Weighted average exercise price	$0.25
Cancelled, Weighted average exercise price	$0.20
Outstanding and exercisable, Weighted average exercise price	$0.25
Outstanding, Average Remaining Contractual Life	'1 year 7 months 1 day

Options_Exercisable_CelLynx_De

Options Exercisable CelLynx (Details) (CelLynx, USD $)	9 Months Ended
Options Exercisable CelLynx (Details) (CelLynx, USD $)	Sep. 30, 2013
CelLynx	'
Options exercisable [Abstract]	'
Beginning, Number of Options	6,400,000
Options, Granted	65,000,000
Options, Cancelled	6,400,000
Ending,Number of Options, outstanding and exercisable	65,000,000
Weighted Average Exercise Price	'
Weighted Average Exercise Price	$0.00
Weighted Average Exercise Price, Granted	$0.00
Weighted Average Exercise Price, Cancelled	$0.00
Weighted Average Exercise Price	$0.00
Weighted Average Remaining Contractual Life	'4 years 5 months 0 days

Options_Assumptions_CelLynx_De

Options Assumptions CelLynx (Details) (CelLynx, USD $) (CelLynx, USD $)	1 Months Ended
	Aug. 28, 2013
CelLynx	'
Stock Price	$0.00
Expected volatility	479.00%
Risk-free Interest	0.04%
Annual Dividend Yield	0.00%
Exepected Life (years)	'4 years 5 months
Stock commitment, shares	5,000,000
Fair value of stock options	$4,500
Stock options commitment expense	$4,500

Warrant_Activity_CelLynx_Group

Warrant Activity - CelLynx Group, Inc. (Details) (USD $) (CelLynx Group, Inc., USD $)	9 Months Ended
	Sep. 30, 2013
CelLynx Group, Inc.	'
Warrant Activity	'
Outstanding at December 31, 2012, Number of Warrants	5,930,000
Granted, Number of shares	'
Exercised, Number of shares	'
Expired, Number of shares	1,430,000
Outstanding and exercisable, Number of Warrants	4,500,000
Weighted Average Exericse Price	'
Outstanding at December31, 2012	$0.79
Granted, Weighted average exercise price	'
Exercised, Weighted average exercise price	'
Expired, Weighted average exercise price	$0.10
Outstanding and exercisable, Weighted average exercise price	$0.96
Outstanding, Average Remaining Contractual Life	'1 year 4 months 0 days

Related_Party_transactions_Det

Related Party transactions (Details) (USD $)	9 Months Ended		59 Months Ended
Related Party transactions (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
Related Party Transactions [Abstract]	'	'	'	'
Date of Agreement	30-Dec-10	'	'	'
Proceeds from Note Payable	$370,000	'	'	'
Issuance of Common Stock	15,600,000	'	'	'
Payment on Note	19,378	97,612	463,701	'
Payment due to Related Party	$472	'	$472	$19,850

Commitments_Details_Narrative

Commitments (Details Narrative) (USD $)	Jul. 24, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Lease montlhly payments	$1,371
Minimum lease payments	$281,154

Litigation_Details_Narrative

Litigation (Details Narrative) (USD $)	9 Months Ended
Litigation (Details Narrative) (USD $)	Sep. 30, 2013
CSS Properties #1	'
Date	'10/21/2010
Allegations	'Past due rent
Alleged Damages	$25,000
CSS Properties #2	'
Date	'8/27/2012
Allegations	'Past due rent
Alleged Damages	24,699
Legal Fees	3,000
Late Charges	2,041
Labor Commission	'
Date	'7/19/2010
Allegations	'Unpaid Wages
Alleged Damages	263,023
LaJolla Cove Investors Inc.	'
Date	'10/16/2012
Allegations	'Breach of contract
Alleged Damages	2,500,000
Legal Fees	300,000
La Jolla Cove Dimissal	'
Date	'1/13/2013
Allegations	'Dimssing Action
Alleged Damages	300,000
Late Charges	302,796
Interest Rate per annum	9.00%
Stock Issued During Period, Shares	125,000
Payment on Loan	10,000
Asher Enterprises, Inc.	'
Date	'3/22/2013
Allegations	'Repayment of notes
Alleged Damages	$81,000

Litigation_Details_Narrative_P

Litigation (Details Narrative) (Parenthetical)	9 Months Ended
Litigation (Details Narrative) (Parenthetical)	Sep. 30, 2013
LaJolla Cove Investors Inc.	'
Damages Sought	'
Damages Sought	Seeking compensatory damages and alleged loss of profits of in excess of $2,500,000, based upon a $150,000 investment made by LA Jolla Cove Investors under certain putative agreements. La Jolla Cove Investors Inc. v. 5Barz International, Inc., 3:12-CV-5333 (N.D. Cal.). On January 3, 2013, the Company and La Jolla Cove Investors, Inc. entered into an agreement for the settlement of the lawsuit for proceeds of $300,000 plus accrued interest from the date of the settlement agreement at a rate of 9%, plus the delivery of 125,000 shares of the common stock of the Company. On January 13, 2013 a stipulation dismissing action without prejudice and without award of attorney’s fees or costs was entered. The Company issued the 125,000 shares but was unable to meet the payment schedule as provided in the settlement agreement. On March 8, 2013 as a result of the default, La Jolla Cove was awarded a judgment in the amount of $300,000 plus accrued interest at a rate of 9% from the date of the settlement agreement. The Company intends to pay the balance due once funded.
Asher Enterprises, Inc.	'
Damages Sought	'The claims allege that damages in the amount of the greater of; (i) 200% x $81,000, the remaining outstanding principle amount of the Note, together with accrued and unpaid interest in the unpaid principle amount of the Notes, plus default interest; or (ii) the “parity value” of the “default amount” paid in shares as defined in the terms of the agreements. The Company intends to file an appearance and defend against the law suit.

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	0 Months Ended		9 Months Ended
	Nov. 18, 2013		Sep. 30, 2013
	Subsequent Event		Office Lease
Units Issued	27,213,904		'
Proceeds from Sale of Warrants	$2,721,390		'
Aggregate Proceeds	2,116,980		'
Line of credit	1,440,768		'
Aggregate funding of line of credit	2,504,106		'
Common stock issued for debt	5,119,574		'
Account payable settlement	92,453		'
Gain on settlement of debt	928,811		'
Price of Stock	$0.30		'
Price per share	$0.10	[1]	'
Monthly Lease Expense	'		8,023
Future minimum lease payments	'		312,897
Stock Issued During Period	1,566,980		'
Settlement of debt for common stock	$596,541		'

[1]	Each unit is comprised of one share and one warrant to acquire a second share, with a two year warrant term.

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash	$143,754	$48,308
Prepaid expenses and deposits	61,075	22,156
TOTAL CURRENT ASSETS	204,829	70,464
Equipment, net	7,015	4,406
OTHER ASSETS:	'	'
Intangible assets	3,387,406	3,387,406
Goodwill	1,140,246	1,140,246
Total other assets	4,527,652	4,527,652
TOTAL ASSETS	4,739,496	4,602,522
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses	2,562,262	2,445,410
Due to escrow agent	52,321	52,321
Accrued derivative liabilities	60,772	'
Notes payable (net of discount)	1,089,882	993,554
TOTAL CURRENT LIABILITIES	3,765,237	3,491,285
Related party loans	472	19,850
TOTAL LIABILITIES	3,765,709	3,511,135
STOCKHOLDERS' EQUITY	'	'
Common stock, $.001 par value, 250,000,000 shares authorized; 160,117,625 shares issued and outstanding as of September 30, 2013 on a pro-forma basis	138,404	117,418
Capital in excess of par value	5,179,130	3,226,802
Deficit accumulated during the development stage	-4,989,290	-2,971,099
Accumulated other comprehensive income	27,250	4,272
Non-controlling interest	618,293	713,994
Total stockholders' equity	973,787	1,091,387
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	4,739,496	4,602,522
Adjustments	'	'
CURRENT ASSETS:	'	'
Cash	-1,566,980	'
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses	-1,018,823	'
Notes payable (net of discount)	-514,398	'
STOCKHOLDERS' EQUITY	'	'
Common stock, $.001 par value, 250,000,000 shares authorized; 160,117,625 shares issued and outstanding as of September 30, 2013 on a pro-forma basis	21,714	'
Capital in excess of par value	2,149,676	'
Deficit accumulated during the development stage	928,811	'
Pro-Forma	'	'
CURRENT ASSETS:	'	'
Cash	1,710,734	'
Prepaid expenses and deposits	61,075	'
TOTAL CURRENT ASSETS	1,771,809	'
Equipment, net	7,015	'
OTHER ASSETS:	'	'
Intangible assets	3,387,406	'
Goodwill	1,140,246	'
Total other assets	4,527,652	'
TOTAL ASSETS	6,306,476	'
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses	1,543,439	'
Due to escrow agent	52,321	'
Accrued derivative liabilities	60,772	'
Notes payable (net of discount)	575,484	'
TOTAL CURRENT LIABILITIES	2,232,016	'
Related party loans	472	'
TOTAL LIABILITIES	2,232,488	'
STOCKHOLDERS' EQUITY	'	'
Common stock, $.001 par value, 250,000,000 shares authorized; 160,117,625 shares issued and outstanding as of September 30, 2013 on a pro-forma basis	160,118	'
Capital in excess of par value	7,328,806	'
Deficit accumulated during the development stage	-4,060,479	'
Accumulated other comprehensive income	27,250	'
Non-controlling interest	618,293	'
Total stockholders' equity	4,073,988	'
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$6,306,476	'